Comprehensive Outcomes for After Cancer Health (COACH)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05349227 |
Recruitment Status :
Recruiting
First Posted : April 27, 2022
Last Update Posted : October 12, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ovarian Cancer Breast Cancer Lung Cancer Gastric Cancer Survivorship | Behavioral: Digital Health Coaching Program Device: Fitbit | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 660 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Intervention Model Description: | Wait list control trial in which 100 patients will be randomized to receive either 6-months of digital coaching immediately followed by 6-months of monitoring or 6-months of monitoring followed by 6-months of digital health coaching. All participants will receive 12 months of patient reported outcomes collection and activity tracking via wrist-worn devices, as well as microbiome collection at baseline and month 6 only. |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | Comprehensive Outcomes for After Cancer Health (COACH): The Feasibility and Impact of an mHealth Augmented Coaching Program for Self-Management in Cancer Survivors |
Actual Study Start Date : | June 23, 2022 |
Estimated Primary Completion Date : | December 2024 |
Estimated Study Completion Date : | December 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Intervention Group
In addition to standard of care services at the participant's respective health system, and study specific collection of clinical, PRO, and wearable data, as well as microbiome specimens, individuals randomized to the intervention group will receive immediate enrollment to a 6-month digital health coaching program followed by 6 months monitoring via PRO, wearable, and clinical data collection. They will collect fecal microbiome samples at baseline (study enrollment) and month 6 following enrollment.
|
Behavioral: Digital Health Coaching Program
Coaching consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application. Device: Fitbit Device: Fitbit A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily. |
Wait List Control Group
In addition to standard of care services, individuals in the wait list control will be monitored via the collection of PRO, clinical, and wearable data for the first 6 months, along with fecal microbiome collection at study enrollment baseline (study enrollment) and month 6. At month 6 these individuals will be enrolled into the 6-month digital health coaching program, during which clinical, PRO and wearable data will continue to be collected. At the completion of the 6-month coaching these individuals will come off study and will not receive additional follow-up.
|
Behavioral: Digital Health Coaching Program
Coaching consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application. Device: Fitbit Device: Fitbit A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily. |
No Intervention: Household Healthy Participants
A cohort of consisting of adults without a cancer diagnosis residing in the same residence as participants, will be consented to collect fecal microbiome specimens to serve as a control for potential regional variation in microbiome dysbiosis. Up to 25 healthy controls will be enrolled per 100 participants at each study site. At sites enrolling fewer than 100 participants, an n up to 25% of the total patient enrollment sample will be approached for enrollment.
|
- Acceptability of coaching intervention [ Time Frame: At 6 months following the start of the coaching intervention ]A 3-item questionnaire evaluating the following: 1) The digital health coaching program is easy to participate in; 2) the digital health coaching program is useful to me; 3) the digital health coaching program is relevant to my survivorship experience. Responses will be provided on a 10-point Likert scale ranging from 1 (Not at all) to 10 (Very Much).
- Feasibility of coaching intervention [ Time Frame: At 6 months following the start of the coaching intervention ]A retention rate greater than or equal to 70%. Retention is defined as individuals who agree to participate in the digital health coaching program completing the 6-months of engagement post-enrollment.
- Change in Self-Efficacy for Managing Chronic Disease [ Time Frame: Change in baseline perception of self-efficacy at 12 months ]A 6-item instrument measures how confident an individual is in engaging in certain health management activities. Responses are provided on a 10-point scale ranging from 1(not at all confident) to 10 (totally confident). A mean score is calculated for the instrument with a higher score indicating higher self-efficacy.
- Change in the National Institutes of Health (NIH) Patient Reported Outcomes Measurement Information System (PROMIS) Short Form v2.0 Physical Function 10a [ Time Frame: Change in baseline perception of physical function at 12 months ]A 12-item instrument assessing respondents' abilities to perform physical tasks and activities of daily living. Items are scored on 5-point Likert scales, with higher scores indicating higher physical functioning.
- Change in Quality of Life as measured by The Functional Assessment of Cancer Therapy - General v4 (FACT-G) [ Time Frame: Change in baseline perception of quality of life at 12 months ]A 27-item instrument using a 5-point Likert scale ranging from 0 (not at all) to 4 (very much) to measure QoL across four dimensions: physical, social/family, emotional and functional. The FACT-G, validated for use with individuals with diverse cancer types, in addition to condition specific items as available by tumor type.
- Change in Anxiety as measured by the PROMIS Anxiety Short Form 8a [ Time Frame: Change in baseline perception of anxiety at 12 months ]An 8-item instrument measuring indicators of anxiety with a recall period over the last 7 days. Responses are provided on a 5-point scale ranging from 1(never) to 5 (always). A summed score is calculated for the instrument with a higher score indicating greater anxiety.
- Change in Depression as measured by the PROMIS Depression Short Form 8a [ Time Frame: Change in baseline perception of depression at 12 months ]An 8-item instrument measuring indicators of depression with a recall period over the last 7 days. Responses are provided on a 5-point scale ranging from 1(never) to 5 (always). A summed score is calculated for the instrument with a higher score indicating greater depression.
- Change in Cognitive Function as measured by the PROMIS Cognitive Function Short Form 8a [ Time Frame: Change in baseline perception of cognitive impairment at 12 months ]An 8-item instrument measuring indicators of cognitive function with a recall period over the last 7 days. Responses are provided on a 5-point scale ranging from 1(never) to 5 (always). A summed score is calculated for the instrument with a higher score indicating greater cognitive impairment.
- Change in Sleep-related Impairment as measured by the PROMIS Sleep related Impairment Short Form 8a [ Time Frame: Change in baseline perception of cognitive impairment at 12 months ]An 8-item instrument measuring indicators of sleep-related impairment with a recall period over the last 7 days. Responses are provided on a 5-point scale ranging from 1(never) to 5 (always). A summed score is calculated for the instrument with a higher score indicating greater sleep-related impairment.
- Change in the PROMIS Brief Sexual Function & Satisfaction Measure Male [ Time Frame: Change in baseline perception of sexual function and satisfaction at 12 months among male participants ]An 11-item instrument measuring indicators of male sexual function and satisfaction with a recall period over the last 30 days. Responses are provided on various 2- to 10-point scales across 10 domains: interest in sexual activity, orgasm ability, orgasm satisfaction, oral discomfort, oral dryness, satisfaction with sex life, erectile function. For each item on the instrument a higher score indicates more of the concept being described.
- Change in the PROMIS Brief Sexual Function & Satisfaction Measure Female [ Time Frame: Change in baseline perception of sexual function and satisfaction at 12 months among female participants ]A 14-item instrument measuring sexual function and satisfaction for women with a recall period over the last 30 days. Responses are provided on various 2- to 10-point scales across 7 domains: interest in sexual activity, lubrication for sexual activity, orgasm ability, orgasm pleasure, oral discomfort, oral dryness, satisfaction with sex life, vaginal discomfort, vulvar discomfort-clitoral, vulvar discomfort-labial. For each item on the instrument a higher score indicates more of the concept being described.
- Change in The Comprehensive Score for Financial Toxicity (COST) [ Time Frame: Change in baseline perception of financial toxicity at 12 months ]An 11-item instrument measuring the financial toxicity of cancer treatment utilizing a five-point ordinal scale ranging from (0- Not at all) to (4- Very much).
- Change in Economic Strain and Resilience in Cancer (ENRICh) [ Time Frame: Change in baseline perception of financial toxicity at 12 months ]An 16-item instrument measuring the financial toxicity of cancer treatment. The first 15 items are rated on an 11-point scale ranging from 0 (lowest financial toxicity burden) to 10 (most severe financial toxicity burden). A final item asks individuals to rank their overall financial situation at the time of the survey compared to prior to their cancer diagnosis, using a 5-point response ranging from much better to much worse.
- Change in symptom burden as measured by the Edmonton Symptom Assessment System-Revised (ESAS-R) [ Time Frame: Change in baseline perception of symptom burden at 12 months ]A 10-item instrument measuring the presence of commonly observed symptoms in individuals with a cancer diagnosis (9 specific items and 1 allowing entry of other problems). Responses for a recall period of the last 24 hours are recorded on an 11-point scale ranging from 0 (none/not present) to 10 (worst possible).
- Dietary Intake as measured by the Diet History Questionnaire (DHQ) III [ Time Frame: Within 2 weeks of microbiome collection at enrollment and month 6 ]An electronic food diary assessment capturing dietary intake over the last 24 hours. The number of items
- Change in medication adherence for individuals taking maintenance therapies [ Time Frame: Change in baseline perception of medication adherence at 12 months ]A three-item instrument used to measure medication adherence, asking about difficulty taking medications on time, average days per week with one dose missed, and the last time a dose was missed. Responses are on differing scales, with higher values meaning better adherence.
- Physical Activity [ Time Frame: From date of enrollment up to 12 months ]Step count will be collected via Fitbits provided to study participants
- Physical Activity [ Time Frame: From date of enrollment up to 12 months ]Minutes of physical activity will be collected via Fitbits provided to study participants
- Digital Engagement [ Time Frame: From date of enrollment up to 12 months ]Frequency, types and duration of engagement with the digital health coaching platform
- Gut Microbiota [ Time Frame: From date of enrollment to 6 months ]16s analysis of fecal microbiome specimens self-collected by participants
- Health Care Utilization [ Time Frame: From date of enrollment to 12 months ]ER visits and unplanned hospitalizations as documented in the electronic health record
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Have primary diagnosis of cancer;
-
Are within 1 year of completion of primary therapy OR have a diagnosis of metastatic cancer
a. For the purpose of this study, primary therapy is defined as treatment of curative intent, first-line or later, from which the individual is advancing to active surveillance or follow-up with or without maintenance therapy
- Are aged 18 years and older;
- Can read and consent to participate in the trial;
- Can read and speak English;
- Can complete study follow-up at pre-specified intervals;
- Have access to mobile technology (e.g. a smart phone or tablet) that would allow engagement in digital health coaching for the collection of PROs and wearable data.
- Agree to wear and have data collected from an activity tracking device
Exclusion Criteria:
- Have a cognitive impairment (as assessed by their provider) that would prohibit the individual from engaging with the digital health coaching program or complete study assessments;
- Have a neurologic, musculoskeletal, or other comorbid condition that would impede their ability to engage in physical activity (as assessed by their provider)
- Have a life expectancy of <6 months, and/or
- Are on active treatment for relapsed disease. a. Individuals with disease progression or relapse which occurs following their consent to participate will be given the option to continue on study if they wish to do so. Data from individuals experiencing disease progression or relapse will be grouped for sub-analysis to explore if and how relapse impacts study outcomes.
Healthy Volunteers must:
- Be adults aged 18 years or older or the age of majority in their state of residence, whichever is older.
- Must reside in the same dwelling as the patient participant
- Can read and consent to participate in the trial;
- Can read and speak English;
- Can complete study follow-up at pre-specified intervals;
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05349227
Contact: Kelly J Brassil, PhD | 205-721-7542 | dgxpharesearch@questdiagnostics.com | |
Contact: Austin Barr, MPH | 205-721-7542 | dgxpharesearch@questdiagnostics.com |
United States, Florida | |
The University of Florida | Recruiting |
Gainesville, Florida, United States, 32610 | |
Contact: Angela R Starkweather, PhD, FAAN 352-273-6321 a.starkweather@ufl.edu | |
Contact: Debra L Lynch Kelly, PhD, FAAN 352-273-6390 dlynchkelly@ufl.edu | |
Principal Investigator: Angela R Starkweather, PhD, FAAN | |
Principal Investigator: Debra L Lynch Kelly, PhD, FAAN | |
United States, Massachusetts | |
Dana Farber Cancer Institute | Recruiting |
Boston, Massachusetts, United States, 02215 | |
Contact: Marilyn Hammer, PhD 347-271-0293 marilynj_hammer@dfci.harvard.edu | |
Contact: Alexi Wright, MD, MPH 617-632-2334 Alexi_Wright@dfci.harvard.edu | |
Principal Investigator: Marilyn Hammer, PhD | |
Principal Investigator: Alexi Wright, MD, MPH | |
United States, Nebraska | |
University of Nebraska Medical Center | Recruiting |
Omaha, Nebraska, United States, 68106 | |
Contact: Rachael Schmidt, DNP 402-559-1889 raschmidt@nebraskamed.com | |
Contact: Robin M Lally, PhD 402-559-5464 robin.lally@unmc.edu | |
Principal Investigator: Robin M Lally, PhD | |
Principal Investigator: Rachael Schmidt, DNP | |
United States, Ohio | |
The Ohio State University Wexner Medical Center | Recruiting |
Columbus, Ohio, United States, 43210 | |
Contact: Laura Flora, BA 614-685-5286 laura.flora@osumc.edu | |
Contact: Elizabeth Arthur, PhD 614-293-0811 liz.arthur@osumc.edu | |
Principal Investigator: Elizabeth Arthur, PhD | |
Principal Investigator: Jessica L Krok-Schoen, PhD | |
United States, Texas | |
The University of Texas MD Anderson Cancer Center | Not yet recruiting |
Houston, Texas, United States, 77030 | |
Contact: Meagan Whisenant, Phd 713-745-2089 Mswhisenant@mdanderson.org | |
Contact: Darcy Ponce, BS 713-745-2247 Dponce@mdanderson.org | |
Principal Investigator: Meagan Whisenant, PhD | |
Sub-Investigator: Debu Tripathy, MD | |
Sub-Investigator: Abbey Kaler, MSN | |
UT Health Houston | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Kaukab I Jafry, MD, MBBS 832-325-6537 Kaukab.I.Jafry@uth.tmc.edu | |
Contact: Martha Thompson 832-325-7706 Martha.Thompson@uth.tmc.edu | |
Principal Investigator: Jessica T Jones, MD |
Principal Investigator: | Marilyn Hammer, PhD | Dana-Farber Cancer Institute | |
Principal Investigator: | Alexi Wright, MD | Dana-Farber Cancer Institute | |
Principal Investigator: | Elizabeth Arthur, PhD | The Ohio State University Wexner Medical Center | |
Principal Investigator: | Jessica Krok-Schoen, PhD | The Ohio State University Wexner Medical Center | |
Principal Investigator: | Robin Lally, PhD | The University of Nebraska | |
Principal Investigator: | Rachael Schmidt, DNP | Nebraska Medicine | |
Principal Investigator: | Angela Starkweather, PhD | University of Florida College of Nursing | |
Principal Investigator: | Jessica Jones, MD | UTHealth Houston McGovern Medical School | |
Principal Investigator: | Debra Lynch-Kelly, PhD | University of Florida College of Nursing | |
Principal Investigator: | Meagan Whisenant, PhD | The University of Texas MD Anderson Cancer Center |
Publications:
Responsible Party: | Pack Health |
ClinicalTrials.gov Identifier: | NCT05349227 |
Other Study ID Numbers: |
202101 ZIANR000020-06 ( U.S. NIH Grant/Contract ) |
First Posted: | April 27, 2022 Key Record Dates |
Last Update Posted: | October 12, 2023 |
Last Verified: | October 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Patient Reported Outcome Measures Physical Activity Digital Coaching Microbiome Wearables |